organization · Reporting owner
Canaan Partners XI LLC
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tyra Biosciences, Inc.TYRA · Entity 4680 | 10% owner | September 17, 2021 | September 20, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tyra Biosciences, Inc.
Report date September 17, 2021 · Filed September 20, 2021
Jointly reported with Canaan XI L.P., Canaan 2020+ Co-Investment L.P. Series 7, Canaan Partners 2020+ Co-Investment LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,936,595 |
Reported balance
After 2021-09-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-09-17 · Conversion · Acquired 3,936,595 · Balance 3,936,595 F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by Canaan XI L.P. ("Canaan XI"). The sole general partner of Canaan XI is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | Direct | 473,396 |
Reported balance
After 2021-09-17 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-09-17 · Conversion · Acquired 473,396 · Balance 473,396 F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7"). The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-09-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-09-17 · Conversion · Disposed 1,333,334 · Balance 0 F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by Canaan XI L.P. ("Canaan XI"). The sole general partner of Canaan XI is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-09-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-09-17 · Conversion · Disposed 182,257 · Balance 0 F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by Canaan XI L.P. ("Canaan XI"). The sole general partner of Canaan XI is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-09-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-09-17 · Conversion · Disposed 182,258 · Balance 0 F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3: The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7"). The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: The shares are held directly by Canaan XI L.P. ("Canaan XI"). The sole general partner of Canaan XI is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.
F3: The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7"). The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Day One Biopharmaceuticals, Inc.
Report date September 21, 2022 · Filed September 22, 2022
Jointly reported with Canaan XI L.P.
Section 16 reporting ended · disclosed 2022-09-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,964,301 |
Last balance in matching sequence
After 2022-09-21 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2022-09-21 · Sale · Disposed 607,497 · Balance 8,470,407 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.27 - $19.26, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Row 2 · 2022-09-21 · Sale · Disposed 6,106 · Balance 8,464,301 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.27 - $19.35, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Row 3 · 2022-09-21 · Other · Disposed 1,500,000 · Balance 6,964,301 F4: On September 21, 2022, the Canaan Fund distributed, for no consideration, 1,500,000 shares of common stock of the issuer to its limited partners and to Canaan XI, the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan XI distributed, for no consideration, the shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.27 - $19.26, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.27 - $19.35, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: On September 21, 2022, the Canaan Fund distributed, for no consideration, 1,500,000 shares of common stock of the issuer to its limited partners and to Canaan XI, the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan XI distributed, for no consideration, the shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2022 Filed Sep 22, 2022 20:00 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | OtherCommon Stock | 1,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-031692 · doc4.xml · nonDerivative · entry 3 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,964,301 F4 · kind: On September 21, 2022, the Canaan Fund distributed, for no consideration, 1,500,000 shares of common stock of the issuer to its limited partners and to Canaan XI, the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan XI distributed, for no consideration, the shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F4 · price: On September 21, 2022, the Canaan Fund distributed, for no consideration, 1,500,000 shares of common stock of the issuer to its limited partners and to Canaan XI, the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan XI distributed, for no consideration, the shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 20:00 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 6,106 | $19.29 | $117,784.74 |
DisclosureSEC source: 0000899243-22-031692 · doc4.xml · nonDerivative · entry 2 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,464,301 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.27 - $19.35, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 20:00 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 607,497 | $18.54 | $11,262,994.38 |
DisclosureSEC source: 0000899243-22-031692 · doc4.xml · nonDerivative · entry 1 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,470,407 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.27 - $19.26, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 20, 2022 Filed Sep 20, 2022 21:47 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 2,266 | $20.10 | $45,546.60 |
DisclosureSEC source: 0000899243-22-031602 · doc4.xml · nonDerivative · entry 5 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,077,904 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.06 - $20.15, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 20, 2022 Filed Sep 20, 2022 21:47 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 146,404 | $19.50 | $2,854,878.00 |
DisclosureSEC source: 0000899243-22-031602 · doc4.xml · nonDerivative · entry 4 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,080,170 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.06 - $19.85, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 21:47 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 76,725 | $20.57 | $1,578,233.25 |
DisclosureSEC source: 0000899243-22-031602 · doc4.xml · nonDerivative · entry 3 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,226,574 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.22 - $21.07, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 21:47 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 3,722 | $22.04 | $82,032.88 |
DisclosureSEC source: 0000899243-22-031602 · doc4.xml · nonDerivative · entry 2 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,303,299 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.98 - $22.28, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 21:47 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 111,585 | $21.53 | $2,402,425.05 |
DisclosureSEC source: 0000899243-22-031602 · doc4.xml · nonDerivative · entry 1 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,307,021 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.98 - $21.97, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 15, 2022 Filed Sep 15, 2022 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 3,314 | $23.73 | $78,641.22 |
DisclosureSEC source: 0000899243-22-031191 · doc4.xml · nonDerivative · entry 6 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,418,606 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.55 - $24.01, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 15, 2022 Filed Sep 15, 2022 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 47,967 | $22.79 | $1,093,167.93 |
DisclosureSEC source: 0000899243-22-031191 · doc4.xml · nonDerivative · entry 5 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,421,920 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 - $23.52, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 384 | $24.29 | $9,327.36 |
DisclosureSEC source: 0000899243-22-031191 · doc4.xml · nonDerivative · entry 4 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,469,887 F5 · price: Price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.28 - $24.29, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 105,727 | $23.68 | $2,503,615.36 |
DisclosureSEC source: 0000899243-22-031191 · doc4.xml · nonDerivative · entry 3 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,470,271 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.25 - $24.23, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 1,003 | $25.01 | $25,085.03 |
DisclosureSEC source: 0000899243-22-031191 · doc4.xml · nonDerivative · entry 2 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,575,998 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 - $25.06, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 23:48 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | SaleCommon Stock | 86,644 | $24.39 | $2,113,247.16 |
DisclosureSEC source: 0000899243-22-031191 · doc4.xml · nonDerivative · entry 1 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,577,001 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 - $24.99, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 21:40 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | OtherCommon Stock | 536,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-049399 · doc4.xml · nonDerivative · entry 1 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,663,645 F1 · kind: On December 21, 2021, Canaan XI L.P. (the "Canaan Fund") distributed, for no consideration, 536,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Canaan Partners XI LLC ("Canaan XI"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan XI distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On December 21, 2021, Canaan XI L.P. (the "Canaan Fund") distributed, for no consideration, 536,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Canaan Partners XI LLC ("Canaan XI"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan XI distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are held directly by the Canaan Fund. Canaan XI is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 22:15 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | OtherCommon Stock | 536,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-047572 · doc4.xml · nonDerivative · entry 1 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,199,645 F1 · kind: On December 8, 2021, Canaan XI L.P. (the "Canaan Fund") distributed, for no consideration, 536,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Canaan Partners XI LLC ("Canaan XI"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan XI distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On December 8, 2021, Canaan XI L.P. (the "Canaan Fund") distributed, for no consideration, 536,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Canaan Partners XI LLC ("Canaan XI"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund. On the same date, Canaan XI distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are held directly by the Canaan Fund. Canaan XI is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries B Preferred Stock · Derivative | 182,258 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036606 · doc4.xml · derivative · entry 5 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Canaan 2020+ Co-Investment L.P. Series 7 · CIK 0001882023 · 10% owner Canaan Partners 2020+ Co-Investment LLC · CIK 0001881618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 473,396 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.direct: The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7"). The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries B Preferred Stock · Derivative | 182,257 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036606 · doc4.xml · derivative · entry 4 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Canaan 2020+ Co-Investment L.P. Series 7 · CIK 0001882023 · 10% owner Canaan Partners 2020+ Co-Investment LLC · CIK 0001881618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 473,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Canaan XI L.P. ("Canaan XI"). The sole general partner of Canaan XI is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries A Preferred Stock · Derivative | 1,333,334 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036606 · doc4.xml · derivative · entry 3 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Canaan 2020+ Co-Investment L.P. Series 7 · CIK 0001882023 · 10% owner Canaan Partners 2020+ Co-Investment LLC · CIK 0001881618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,463,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Canaan XI L.P. ("Canaan XI"). The sole general partner of Canaan XI is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 473,396 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036606 · doc4.xml · nonDerivative · entry 2 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Canaan 2020+ Co-Investment L.P. Series 7 · CIK 0001882023 · 10% owner Canaan Partners 2020+ Co-Investment LLC · CIK 0001881618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.direct: The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7"). The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| September 17, 2021 Filed Sep 20, 2021 21:16 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 3,936,595 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036606 · doc4.xml · nonDerivative · entry 1 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Canaan 2020+ Co-Investment L.P. Series 7 · CIK 0001882023 · 10% owner Canaan Partners 2020+ Co-Investment LLC · CIK 0001881618 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,936,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Canaan XI L.P. ("Canaan XI"). The sole general partner of Canaan XI is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionSeries B Preferred Stock · Derivative | 148,279 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021571 · doc4.xml · derivative · entry 5 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 148,279 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F3 · price: Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F3 · derivative.exercise_date: Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F3 · derivative.expiration_date: Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F3 · derivative.underlying_shares: Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners XI LLC ("Canaan XI", and together with the Canaan Fund, the "Canaan Entities"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionSeries A Preferred Stock · Derivative | 7,328,497 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021571 · doc4.xml · derivative · entry 4 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,328,497 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F1 · price: Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F1 · derivative.exercise_date: Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F1 · derivative.expiration_date: Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F1 · derivative.underlying_shares: Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners XI LLC ("Canaan XI", and together with the Canaan Fund, the "Canaan Entities"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | PurchaseCommon Stock | 13,000 | $16.00 | $208,000.00 |
DisclosureSEC source: 0000899243-21-021571 · doc4.xml · nonDerivative · entry 3 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,735,645 F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners XI LLC ("Canaan XI", and together with the Canaan Fund, the "Canaan Entities"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionCommon Stock | 148,279 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021571 · doc4.xml · nonDerivative · entry 2 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,722,645 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F3 · price: Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners XI LLC ("Canaan XI", and together with the Canaan Fund, the "Canaan Entities"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:12 UTC | Day One Biopharmaceuticals, Inc. DAWN · Entity 51180 | ConversionCommon Stock | 7,328,497 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021571 · doc4.xml · nonDerivative · entry 1 Canaan XI L.P. · CIK 0001712417 · 10% owner Canaan Partners XI LLC · CIK 0001850694 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,574,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F1 · price: Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration. F2 · ownership.direct: These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners XI LLC ("Canaan XI", and together with the Canaan Fund, the "Canaan Entities"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.